Physician profile
Kara Veit
NPI 1134340144
$6,356.39
in general payments reported to CMS, 2019-2025
30 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,087 · 2022: $1,150 · 2023: $859 · 2024: $1,253 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033 · Education: $85.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,033.23 |
| Education | $85.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.68 | 2021-2025 | |
| Amgen INC. | $595.28 | 2021-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $526.23 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $510.84 | 2021 | |
| Lilly USA, LLC | $458.38 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $390.97 | 2021-2025 | Dupixent |
| Pfizer INC. | $382.11 | 2021-2025 | |
| Leo Pharma INC. | $366.66 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $322.74 | 2021-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $313.15 | 2023-2024 | Sotyktu |
| Incyte Corporation | $235.89 | 2021-2024 | Opzelura |
| Ucb, INC. | $220.98 | 2022-2025 | Bimzelx |
| Genzyme Corporation | $173.85 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.18 | 2021-2024 | Cabtreo |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $114.73 | 2021-2023 | Blu-U, Odomzo |
| Galderma Laboratories, L.P. | $102.28 | 2021-2025 | Nemluvio, Aklief |
| Epi Health, LLC | $66.16 | 2021-2022 | |
| Merz North America, INC. | $39.27 | 2025 | |
| Krystal Biotech INC | $38.91 | 2024 | Vyjuvek |
| Biofrontera INC. | $38.07 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $36.96 | 2024 | Vtama |
| Blueprint Medicines Corporation | $32.03 | 2024 | Ayvakit |
| Mayne Pharma Commercial LLC | $31.38 | 2022 | |
| Organon LLC | $25.94 | 2025 | |
| Verrica Pharmaceuticals INC. | $22.83 | 2024 | Ycanth |
| Almirall LLC | $20.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.40 | 2024 | Spevigo |
| Qiagen, LLC | $19.18 | 2021 | |
| Mission Pharmacal Company | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Veit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.